Galapagos reported EUR61.25M in Gross Profit on Sales for its fiscal quarter ending in March of 2025.


Gross Profit On Sales Change Date
argenx SE USD 837.21M 127.34M Jun/2025
AstraZeneca USD 11.98B 637M Jun/2025
Biogen USD 2.04B 238.8M Jun/2025
Genmab DKK 868M 195M Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
GlaxoSmithKline GBP 5.82B 229M Jun/2025
GRIFOLS EUR 743.8M 49.13M Jun/2025
Hikma Pharmaceutical USD 692M 64M Dec/2024
Incyte USD 1.14B 151.67M Jun/2025
Merck EUR 3.03B 118M Jun/2025
Neurocrine Biosciences USD 676.2M 112.8M Jun/2025
Novartis USD 11.51B 1.12B Jun/2025
Roche Holding CHF 11.69B 48M Dec/2024
Sanofi EUR 7.74B 26M Jun/2025
UCB EUR 2.46B 520M Dec/2024
Vertex Pharmaceuticals USD 2.56B 150M Jun/2025